Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dnaJP1 in Rheumatoid Arthritis
NCT07013110Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Nov 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of dnaJP1 in rheumatoid arthritis (RA). Started Jun 2025; status: recruiting.
02
Drugs
dnaJP1
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07013110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013110.